J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, X.
Right arrow Articles by Sowinski, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, X.
Right arrow Articles by Sowinski, K. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PHARMACOKINETICS

Gatifloxacin Pharmacokinetics in Healthy Men and Women

Xin Zhang, MS, Brian R. Overholser, PharmD, Michael B. Kays, PharmD and Kevin M. Sowinski, PharmD

From the Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Purdue University, Indianapolis and West Lafayette, Indiana (Ms Zhang, Dr Overholser, Dr Kays, Dr Sowinski); Department of Medicine, School of Medicine, Indiana University, Indianapolis, Indiana (Dr Overholser, Dr Kays, Dr Sowinski). Supported in part by grants from Bristol-Myers Squibb Company (Princeton, NJ) and by grant M01RR00750 from the National Institutes of Health (Bethesda, Md). Presented in part at the 106th Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, Orlando, Florida.

The sex-based pharmacokinetics of gatifloxacin were investigated. Healthy subjects (6 men, 6 women) received a single oral dose of gatifloxacin 400 mg. Blood and urine samples were collected, and gatifloxacin concentrations were determined by high-performance liquid chromatography. Pharmacokinetic parameters were estimated by fitting appropriate models to the serum concentration-time data using ADAPT II. Linear regression analysis was used to determine the influence of sex and weight on the oral clearance (CLs/F) and apparent steady-state volume of distribution (Vss/F) of gatifloxacin. Women had a significantly smaller Vss/F compared to men (93.5 ± 21.3 L vs 128.8 ± 16.2 L, P = .009); however, there was no significant difference when normalized for total body weight (TBW) or lean body weight (LBW). Neither CLs/F nor peak serum concentration (Cmax) was significantly different between sexes, although Cmax was 25% higher in women (P = .06). Regression analyses revealed that TBW (R2 = .63) and LBW (R2 = .65) were strong predictors of Vss/F. Given the smaller Vss/F, women may have slightly higher maximum concentrations, but these differences are unlikely to have clinical significance.

Key Words: Oral pharmacokinetics • gatifloxacin • sex differences

Address for reprints: Kevin M. Sowinski, PharmD, Purdue University, Department of Pharmacy Practice, W7555 Myers Building, WHS, 1001 West 10th Street, Indianapolis, IN 46202; e-mail: ksowinsk{at}iupui.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Clinical Pharmacology